Clinical Trials

48 enrolled

Gynecologic

Ovarian Neoplasms

NCT05027386 2026-02-05

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.

Phase 1/2 Recruiting

125 enrolled

CNS

Neuroblastoma

NCT05139095 2026-02-05

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

70 enrolled

Gynecologic

Gestational Trophoblastic Disease

NCT07353684 2026-01-20

Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer

49 enrolled

Adebrelimab

NCT07311408 2025-12-31

SHR-2554

40 enrolled

Stomach Neoplasms

NCT06576973 2025-12-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT06925516 2025-11-28

ACADEMY

38 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06349317 2025-09-29

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

33 enrolled

Carcinoma, Hepatocellular

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Salivary Gland Neoplasms

NCT07105748 2025-08-17

TASK-05

45 enrolled

Liver Neoplasms

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06893887 2025-07-02

ICT-HCC

Phase NA Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT06831175 2025-06-03

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

28 enrolled

Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

NCT06429696 2025-05-28

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

40 enrolled

Small Cell Lung Cancer Extensive Stage

NCT04072042 2025-05-14

BIOVAS

Sarcoma

NCT06483282 2025-04-15

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

38 enrolled

Small Cell Lung Cancer Limited Stage

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05512481 2025-03-03

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

60 enrolled

Dermatologic

Melanoma

NCT05192798 2025-02-27

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

128 enrolled

Triple Negative Breast Neoplasms

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT06480864 2025-01-06

Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

Phase NA Recruiting

38 enrolled

Small Cell Lung Carcinoma

NCT05613478 2024-12-31

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

130 enrolled

Carcinoma, Hepatocellular

NCT06749691 2024-12-27

LIAES

Small Cell Lung Carcinoma

NCT06418594 2024-12-10

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

HER2-negative Breast Cancer Brain Metastases

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

75 enrolled

Locally Advanced Thyroid Gland Carcinoma

NCT04501705 2024-10-15

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

Phase NA Recruiting

29 enrolled

CNS

Meningioma

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT06454578 2024-08-01

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Carcinoma, Hepatocellular

NCT05412589 2024-07-31

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Liver Neoplasms

NCT04318730 2024-07-17

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

21 enrolled

Endocrine

Adrenocortical Carcinoma

NCT06438627 2024-07-16

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

164 enrolled

Nasopharyngeal Carcinoma

NCT06485271 2024-07-03

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Recruiting

504 enrolled

Stomach Neoplasms

NCT06475209 2024-06-26

Adebrelimab + Apatinib in SCLC Maintenance Therapy

60 enrolled

SCLC

NCT04834674 2024-06-25

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

20 enrolled

Cholangiocarcinoma

NCT06447623 2024-06-07

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

184 enrolled

Advanced Breast Cancer

NCT06415669 2024-05-29

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Stomach Neoplasms

NCT06181032 2024-04-30

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Phase 1 Recruiting

Biliary Tract Malignancies

NCT06280508 2024-04-23

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

40 enrolled

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

NCT06296563 2024-04-17

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

20 enrolled

Cholangiocarcinoma

NCT06363825 2024-04-17

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

57 enrolled

Carcinoma, Hepatocellular

NCT06339619 2024-04-01

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

32 enrolled

Esophageal Squamous Cell Carcinoma

NCT05905887 2024-02-28

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

48 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05924997 2024-02-21

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase 1/2 Recruiting

52 enrolled

Carcinoma, Hepatocellular

NCT05759572 2024-02-06

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

145 enrolled

Breast Cancer Metastatic

NCT05069857 2023-11-22

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06099821 2023-10-26

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

39 enrolled

Digestive System Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Neoplasms

NCT05854849 2023-05-11

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

244 enrolled